DavidJohnsonEinsteinMD

Genitourinary Oncology, Hematologic Oncology

Attending Physician, BIDMC; Assistant Professor of Medicine, Harvard Medical School

Dr. Einstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Merit Award in Palliative Care Conquer Cancer Foundation of ASCO, 2014
Excellence in Teaching Award Tufts University School of Medicine, 2014
Notable Teaching Citation Tufts Medical Center Department of Medicine, 2013
Edgar J. Boell Prize Yale University Department of Biology, 2007
Best Poster Intensive Biology and Molecular Biophysics and Biochemistry Division, Yale University Department of Biology Poster Day, 2007
Richter Summer Fellowship Jonathan Edwards College at Yale University, 2006
Join now to see all

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer Start of enrollment: 2018 Oct 18
Active, not recruiting
Phase 2
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2021 May 21
Withdrawn
Phase 2
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors Start of enrollment: 2020 May 11
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Avelumab, Palbociclib and Axitinib in Advanced RCC Start of enrollment: 2024 May 31
Withdrawn
Phase 2
Roles: Principal Investigator, Contact
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma Start of enrollment: 2021 Jun 04
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial Start of enrollment: 2024 Jan 01
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression Start of enrollment: 2023 Jan 19
Recruiting
Early Phase 1
Roles: Contact, Principal Investigator
Join now to see all

PubMed

2 citations
A genetic basis for cancer sex differences revealed in Xp11 translocation renal cell carcinoma.
Mingkee Achom, Ananthan Sadagopan, Chunyang Bao, Fiona McBride, Qingru Xu
Biorxiv. 2023-08-06
2 citations
A genetic basis for sex differences in Xp11 translocation renal cell carcinoma.
Mingkee Achom, Ananthan Sadagopan, Chunyang Bao, Fiona McBride, Jiao Li
Cell. 2024-10-03
113 citations
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.
Katherine L. Morel, Anjali V. Sheahan, Deborah L. Burkhart, Sylvan C. Baca, Nadia Boufaied
Nature Cancer. 2021-03-22

Journal Articles

The ethical imperative of healthy paternalism in advance-directive discussions at the end of life
Einstein DJ, Ladin K, and Mathew P, JAMA Oncol, 1/25/2016
Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey
Einstein DJ, Einstein KL, and Mathew P, J Palliat Med, 1/1/2015
A problematic palsy: an exercise in clinical reasoning
Einstein DJ, Trowbridge RL, and Rencic J, J Gen Int Med, 1/1/2015
Knot
Einstein DJ, Ann Intern Med, 1/1/2012
Join now to see all

Abstracts/Posters

"Expanded Prostate Cancer Index Composite-26 Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life after Treatment for Lo...
Einstein DJ, American Urological Association Annual Meeting, San Diego, CA, 1/1/2016
"Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey."
Einstein DJ, ASCO Palliative Care in Oncology Symposium, Boston, MA, 1/1/2014

Lectures

"'Who Am I to Say?' The Role of Residents in Advance Care Planning."
Boston, MA - 1/1/2016

CAR-T Immunotherapy for Prostate Cancer?September 16th, 2024
Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual MeetingApril 8th, 2022
New Treatment Approved for Late-Stage Prostate CancerApril 7th, 2022
Join now to see all